1-溴-2-(三苯基甲氧基)乙烷 | 102478-39-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: 1-溴-2-(三苯基甲氧基)乙烷
• 英文名称: 1-bromo-2-trityloxyethane
• 英文别名: 1-bromo-2-triphenylmethyloxy-ethane；((2-bromoethoxy)methanetrityl)tribenzene；1-bromo-2-(triphenylmethoxy)ethane；2-Bromoethyl trityl ether；[2-bromoethoxy(diphenyl)methyl]benzene
• CAS: 102478-39-7
• 化学式: C₂₁H₁₉BrO
• 分子量: 367.285
• InChiKey: CHQAQRIPXQLTME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-溴-2-(三苯基甲氧基)乙烷 在 lithium hydroxide 、 potassium carbonate 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 79.0h， 生成 1-<2-(triphenylmethoxy)ethyl>-3-piperidinecarboxylic acid
  参考文献：
  名称：

  Structure-activity studies on benzhydrol-containing nipecotic acid and guvacine derivatives as potent, orally-active inhibitors of GABA uptake

  摘要：

  The introduction of lipophilic groups onto the ring nitrogen of nipecotic acid and guvacine, two known GABA uptake inhibitors, afforded potent, orally-active anticonvulsant drugs. A series of compounds is reported which explores the structure-activity relationships (SAR) in this series. Among the areas explored: side-chain SAR (aromatic-, heterocyclic-, and tricyclic-containing side chains) and modifications to the tetrahydropyridine ring. The benzhydrol ether-containing side chains afforded the most potent compounds with several exhibiting in vitro IC50 values for GABA uptake of <1 muM (including 5, Table 1; 37, 43, Table IV; and 44, Table V). Compound 44 was selected for extensive evaluation and subsequently progressed to Phase 1 clinical trials with severe adverse effects seen after single dose administration to humans.

  DOI：

  10.1021/jm00100a032
• 作为产物：
  描述：

  1-tosyloxy-2-triphenylmethyloxy-ethane 在 lithium bromide 作用下， 以 丙酮 为溶剂， 反应 3.0h， 以98%的产率得到1-溴-2-(三苯基甲氧基)乙烷
  参考文献：
  名称：

  鼠薄荷素的合成

  摘要：

  3-苯甲氧基-3,3-二甲基丙醛（）在八个方便的步骤中转化为C 18-醛中间体。在缺少C中的合成的主要步骤7 -单元是乙酰乙酸甲酯和磷酸酯衍生物的顺式选择性甲基化γ-alkoxyethylation 。中间体和通过已知方法转化为月桂烯醇（）。

  DOI：

  10.1016/s0040-4020(01)96076-4

文献信息

• [EN] INHIBITORS OF HEPATITIS C VIRUS POLYMERASE<br/>[FR] INHIBITEURS DE POLYMÉRASE DU VIRUS DE L'HÉPATITE C
  申请人：COCRYSTAL PHARMA INC

  公开号：WO2016154241A1

  公开（公告）日：2016-09-29

  The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

  本发明提供了一种由一般式I表示的化合物，以及其药学上可接受的盐，其中L和A（以及进一步的取代基）如本文中的类和子类中所定义，并且包括这些化合物的组合物（例如，药物组合物），这些化合物可用作丙型肝炎病毒聚合酶的抑制剂，因此可用作治疗HCV感染的药物。
• [EN] PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION<br/>[FR] DÉRIVÉS DE PYRROLOPYRIMIDINE UTILES EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE LA GRIPPE
  申请人：COCRYSTAL PHARMA INC

  公开号：WO2018200425A1

  公开（公告）日：2018-11-01

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas l-lll, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者中流感病毒复制的方法，减少生物样本或患者中流感病毒的数量，以及治疗患者的流感，包括向所述生物样本或患者投予任何一种代表为Formula l-lll的化合物或其药学上可接受的盐的安全有效量。一种药物组合物包括这种化合物或其药学上可接受的盐的安全有效量，以及药学上可接受的载体、辅料或溶剂。
• Discovery of 3-(1<i>H</i>-Indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a Potent and Selective Inhibitor of Protein Kinase C Isotypes
  作者：Jürgen Wagner、Peter von Matt、Richard Sedrani、Rainer Albert、Nigel Cooke、Claus Ehrhardt、Martin Geiser、Gabriele Rummel、Wilhelm Stark、Andre Strauss、Sandra W. Cowan-Jacob、Christian Beerli、Gisbert Weckbecker、Jean-Pierre Evenou、Gerhard Zenke、Sylvain Cottens

  DOI：10.1021/jm901108b

  日期：2009.10.22

  A series of novel maleimide-based inhibitors of protein kinase C (PKC) were designed, synthesized, and evaluated. AEB071 (1) was found to be a potent, selective inhibitor of classical and novel PKC isotypes. 1 is a highly efficient immunomodulator, acting via inhibition of early T cell activation. The binding mode of maleimides to PKCs, proposed by molecular modeling, was confirmed by X-ray analysis

  设计，合成和评估了一系列新型的基于马来酰亚胺的蛋白激酶C（PKC）抑制剂。发现AEB071（1）是经典和新型PKC同种型的有效选择性抑制剂。图1是高效的免疫调节剂，其通过抑制早期T细胞活化而起作用。通过分子建模提出的马来酰亚胺与PKCs的结合模式，通过对PKCα活性位点中结合的1个X射线分析进行了证实。
• Gold(I)-Catalyzed Synthesis of Unsymmetrical Ethers Using Alcohols as Alkylating Reagents
  作者：Yongxiang Liu、Xiaoyu Wang、Yanshi Wang、Chuan Du、Hui Shi、Shengfei Jin、Chongguo Jiang、Jianyong Xiao、Maosheng Cheng

  DOI：10.1002/adsc.201401097

  日期：2015.3.23

  microwave‐irradiated alcohol‐protecting strategy based on gold catalysis utilizing benzyl alcohol, tert‐butyl alcohol and triphenylmethanol as alkylating reagents has been developed. This protecting strategy has wide functional group tolerance with satisfactory yields for the majority of the selected alcohols. The mechanism of this transformation was probed with oxygen‐18 isotope labelled alcohols assisted by

  基于苄基醇，叔丁醇和三苯甲醇作为烷基化试剂的金催化的微波辐射醇保护策略已经被开发出来。对于大多数选定的醇，该保护策略具有宽泛的官能团耐受性和令人满意的产率。在GC-MS技术和化学动力学实验的辅助下，用氧18同位素标记的醇探索了这种转变的机理。该策略为有机合成中的苄基，叔丁基和三苯甲基醚的制备提供了一种有效，直接和替代的方法。
• SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF
  申请人：Chen Jianxin

  公开号：US20080096903A1

  公开（公告）日：2008-04-24

  Sulfamoyl-containing compounds are disclosed, having utility as inhibitors of disease-related targets, such as Heat Shock Protein 90 (HSP90), and which are useful for treating disorders, e.g., proliferative disorders, including HSP90-mediated disorders. Methods for preparing and using the disclosed compounds are also described.

  披露了含有磺酰氨基的化合物，这些化合物可用作疾病相关靶点的抑制剂，例如热休克蛋白90（HSP90），并且可用于治疗疾病，例如增殖性疾病，包括HSP90介导的疾病。还描述了制备和使用所披露化合物的方法。